Lowering Drug Prices for Americans
President Trump recently revealed new agreements with top pharmaceutical companies to cut prescription drug prices for Americans. This plan aims to match the lowest prices paid by other developed countries. The companies involved include Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis, and Sanofi.
These agreements target many expensive medications used to treat chronic conditions like diabetes, arthritis, multiple sclerosis, asthma, and certain cancers. By allowing state Medicaid programs to access these lower prices, billions of dollars in savings are expected. This plan is a significant step in enhancing support for American patients, especially the most vulnerable.
Additionally, the agreements ensure that foreign nations won’t exploit U.S. innovation by securing low prices on new medicines. Companies must also redirect profit gains from international sales back to American healthcare consumers.
Significant Price Reductions
When patients buy directly from TrumpRx, they can expect substantial discounts. Here are a few examples:
- Amgen’s cholesterol medication, Repatha, drops from $573 to $239.
- Bristol Myers Squibb’s HIV drug, Reyataz, is slashed from $1,449 to $217.
- Boehringer Ingelheim’s diabetes medication, Jentadeuto, goes from $525 to $55.
- Genentech’s flu medication, Xofluza, will now cost $50 instead of $168.
- Gilead’s Hepatitis C treatment, Epclusa, drops from $24,920 to $2,425.
- GSK’s asthma inhaler, Advair Diskus, falls from $265 to $89.
- Merck’s diabetes drug, Januvia, is reduced from $330 to $100.
- Novartis’s multiple sclerosis drug, Mayzent, decreases from $9,987 to $1,137.
- Sanofi’s blood thinner, Plavix, will now be just $16, down from $756; insulin will cost $35 a month.
Investing in American Health Security
These manufacturers are also committing to invest over $150 billion in U.S. operations. As part of this initiative, some companies will donate essential pharmaceutical ingredients to the Strategic Active Pharmaceutical Ingredients Reserve. This move is aimed at reducing reliance on foreign sources and ensuring the U.S. has adequate supplies during emergencies.
- GSK will provide 98.8 kg of albuterol for asthma inhalers.
- Bristol Myers Squibb will contribute 6.5 tons of apixaban, a blood thinner.
- Merck will donate 3.5 tons of ertapenem, an antibiotic for complex infections.
Putting American Patients First
President Trump’s approach seeks to ensure that American patients no longer bear the burden of high drug costs to offset lower prices abroad. A 2025 executive order aimed to align U.S. drug prices with those in other developed nations, stating the need for pharmaceutical companies to provide fair pricing.
Since then, numerous agreements have been made to bring down medication costs for millions of Americans. These efforts include a deal with the U.K. to ensure they pay a fair price for new drugs, reflecting a commitment to balanced pricing across borders.
As we look at the growing trend towards more affordable healthcare options, a recent study found that 8 in 10 Americans support initiatives aimed at lowering drug prices. This reflects a broad concern over rising costs in the healthcare sector. Ensuring better access to affordable medications could significantly impact public health outcomes in the years to come.
For more detailed statistics on drug pricing and patient perspectives, you can check the recent report from the Kaiser Family Foundation.
